Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Use of Cryopressotherapy in Patiens Undergoing Total Knee Replacement to Improve Clinical Outcome

NCT07456787 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2025-09-29
Last updated
2026-03-06

Condition(s) studied

Total Knee Arthroplasty\(TKA\)Osteoartrosi

Investigational drug(s) / intervention(s)

CryopressotherapyIce pack

Cryopressotherapy: Comparison between Cryopressotherapy and ice pack in patients undergoing Total Knee Arthroplasty to improve clinical outcomes

Ice pack: Comparison between ice pack and cryopressotherapy

Study summary

The purpose of this study is to evaluate the effectiveness of cryopressotherapy in patients undergoing total knee arthroplasty by assessing clinical improvement using the KOOS at 14 days after surgery.

Analysis of the knee Range of Motion (ROM) in the preoperative phase, at the predischarge visit, and at the follow-up visit for suture removal performed 14 days after surgery.

Analysis of PROMs such as: Oxford Knee Score (OKS), Joint Forgotten (JF), NRS score, and SF-12.

These questionnaires will be collected in the preoperative phase, at the predischarge visit, and at the follow-up visit for suture removal performed 14 days after surgery.

To evaluate whether cryopressotherapy leads to an improvement in predischarge hemoglobin (Hb) levels.

To assess whether cryopressotherapy reduces the circumference and subcutaneous fluid accumulation of the operated limb.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Candidates for elective total knee arthroplasty surgery (indication determined solely by the Orthopedic Surgeon) * Patients aged between 18 and 80 years (inclusive) for both groups * Body Mass Index (BMI) between 18 and 35 kg/m² * Willingness and ability to provide informed consent * Patients with non-inflammatory degenerative knee joint disease, including osteoarthritis Exclusion Criteria: * Use of medications that may interfere with muscle metabolism * Bone metastases or diseases at the surgical site * Presence or suspicion of infection at the knee * Inability to provide informed consent * Obesity (BMI ≥ 35 kg/m²) * Patients requiring revision surgery of total knee arthroplasty * Patients with pacemakers and/or mechanical implants or those who may be affected by BIA interference

Primary outcome measure(s)

  • Change From Baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS) at 14 Days Postoperatively — Preoperative assessment and 14 days postoperatively.
    The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a patient-reported questionnaire consisting of 5 subscales: Pain, Symptoms, Activities of Daily Living (ADL), Sport and Recreation Function, and Knee-Related Quality of Life. Each subscale is scored separately and transformed to a 0-100 scale, where 0 represents extreme knee problems and 100 represents no knee problems. The outcome measure is the change from preoperative baseline to 14 days postoperatively in KOOS scores

Trial sites (1)

FacilityCityRegionStatus
IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Milan 20173 Milan Italy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07456787 on ClinicalTrials.gov ↗ ← All trials in Italy